Drugs / CSL040
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05937581 | Sep 2023 → Dec 2025 | complement deficiency | CSL Behring | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05937581 ↗ |
| Route | Intravenous | “IV Administration” NCT05937581 ↗ |